Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On February 24, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreeme
Unregistered Sales of Equity Securities. The issuance and sale of the Securities described in Item 1.01 above is hereby incorporated by reference into this Item
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1* Form of Common Stock Purchase Warrant 4.2* Form of Pre-Funded Warrant 10.1* Securi